| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Published online before print July 9, 2007
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||







From the Molecular Medicine Division,* The Walter and Eliza Hall Institute of Medical Research, Victoria, Australia; The Bionic Ear Institute,
East Melbourne, Victoria, Australia; Department of Otolaryngology,
University of Melbourne, East Melbourne, Victoria, Australia; and the Department of Cardiovascular Research,
Berlex Biosciences, Richmond, California
Defective proteolysis has been implicated in hearing loss through the discovery of mutations causing autosomal recessive nonsyndromic deafness in a type II transmembrane serine protease gene, TMPRSS3. To investigate their physiological function and the contribution of this family of proteases to the auditory function, we analyzed the hearing status of mice deficient for hepsin, also known as TMPRSS1. These mice exhibited profound hearing loss with elevated hearing thresholds compared with their heterozygous and wild-type littermates. Their cochleae showed abnormal tectorial membrane development, reduction in fiber compaction in the peripheral portion of the auditory nerve, and decreased expression of the myelin proteins myelin basic protein and myelin protein zero. In addition, reduced level of the large conductance voltage- and Ca2+-activated K+ channel was detected in the sensory hair cells of Tmprss1-null mice. We examined thyroid hormone levels in Tmprss1-deficient mice, as similar cochlear defects have been reported in animal models of hypothyroidism, and found significantly reduced free thyroxine levels. These data show that TMPRSS1 is required for normal auditory function. Hearing impairment present in Tmprss1-null mice is characterized by a combination of various structural, cellular, and molecular abnormalities that are likely to affect different cochlear processes.
This article has been cited by other articles:
![]() |
W. Li, B.-E. Wang, P. Moran, T. Lipari, R. Ganesan, R. Corpuz, M. J.C. Ludlam, A. Gogineni, H. Koeppen, S. Bunting, et al. Pegylated Kunitz Domain Inhibitor Suppresses Hepsin-Mediated Invasive Tumor Growth and Metastasis Cancer Res., November 1, 2009; 69(21): 8395 - 8402. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. J. Ramsay, V. Quesada, M. Sanchez, C. Garabaya, M. P. Sarda, M. Baiget, A. Remacha, G. Velasco, and C. Lopez-Otin Matriptase-2 mutations in iron-refractory iron deficiency anemia patients provide new insights into protease activation mechanisms Hum. Mol. Genet., October 1, 2009; 18(19): 3673 - 3683. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. H. Bugge, T. M. Antalis, and Q. Wu Type II Transmembrane Serine Proteases J. Biol. Chem., August 28, 2009; 284(35): 23177 - 23181. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. J. Ramsay, J. D. Hooper, A. R. Folgueras, G. Velasco, and C. Lopez-Otin Matriptase-2 (TMPRSS6): a proteolytic regulator of iron homeostasis Haematologica, June 1, 2009; 94(6): 840 - 849. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. P. Korovkina, S. J. Stamnes, A. M. Brainard, and S. K. England Nardilysin convertase regulates the function of the maxi-K channel isoform mK44 in human myometrium Am J Physiol Cell Physiol, March 1, 2009; 296(3): C433 - C440. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |